DOYLESTOWN, PA, January 14, 2003 - The Quigley Corporation (NASDAQ: QGLY), today announced that a Patent Application previously assigned to The Quigley Corporation for an all-natural compound was found effective in reducing the impact of influenza. Quigley Pharma Inc., the Company's wholly owned ethical pharmaceutical subsidiary, developed the formula.

The study was designed to test the efficacy of the Quigley Pharma formula in a more advanced influenza model.

Retroscreen Virology Ltd, the research virology company affiliated with the University of London, conducted the study. Professor John S. Oxford, the firm's senior scientist, is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. He is the co-author of two standard texts on Influenza and Virology and has published 250 scientific papers throughout the world.

The study report concluded that "the data indicated that intranasal administration of the (Quigley Pharma) nasal spray was effective in this model, with slightly differing symptom resolutions."

In a previous statement, Professor Oxford said that an independent audit of his previously conducted in-vitro study of the new Quigley Pharma formulation had been confirmed to be effective in killing three virulent strains of current Influenza 'A' and 'B' viruses. At that time he recommended that additional model studies be undertaken, which, if successful, he would publish in a reputable medical journal.

These additional studies have now been successfully completed, and according to Professor Oxford, are encouraging. Professor Oxford said "it is now important that further investigations are considered to determine whether lower concentrations of the test compounds will be as effective and that there is a dose response. When we have sufficient data regarding toxicity, a human study might be considered. That study would consist of human influenza challenge testing."

Guy J. Quigley, President, Chairman and Chief Executive Officer of The Quigley Corporation, stated: "At the conclusion of the dosage response and toxicity testing, we will consider the most appropriate strategy for the Company to pursue in this process. We are continuing our ongoing research and development efforts at Quigley Pharma. Under the direction of Dr. Richard Rosenbloom, we hope to continue developing an exciting pipeline of potential new all-natural medications to bring to the market."

Dr. Rosenbloom stated: "We are greatly encouraged by the clinical and pre-clinical studies conducted on Quigley Pharma formulations to date and the continuing progress toward the approval process."

Influenza can cause localized epidemics and global pandemics of acute respiratory infections. Although influenza is mostly associated with a benign and self-limiting condition, there is a significant link between mortality and infection of children, elderly, and the persons with impaired immunity systems.

About The Quigley Corporation
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG(tm)) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG(tm)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

No claims are being made for the potential medicine discussed in this press release to be safe, effective, or approved by the Federal Food and Drug Administration (FDA).

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.